NCT00764751已完成2 期
LEO 19123 Cream in the Treatment of Psoriasis Vulgaris
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- LEO Pharma
- 入组人数
- 51
- 试验地点
- 1
- 主要终点
- The Percentage Change in PASI (Psoriasis Area Severity Index)
研究概览
简要总结
This study will compare the efficacy and safety of once daily treatment of LEO 19123 cream versus Dovonex® cream (applied twice daily) and versus LEO 19123 cream vehicle alone (applied twice daily) in subjects with psoriasis vulgaris. Subject will be treated for 4 weeks. All subjects will apply LEO 19123 cream to psoriasis lesions on the left or right side of the body and either Dovonex® cream or cream vehicle to lesions on the other side.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent to be obtained prior to any trial related procedure, including washout.
- •Clinical diagnosis of psoriasis vulgaris involving trunk and/or arms and/or legs with a symmetrical distribution amenable to treatment with a maximum of 50 g/week of topical medication on each side of the body. At Visit 1, there should not be a difference between the right and left side of more than 1 for each of the PASI criteria (redness, thickness and scaliness).
- •A minimum PASI score for extent of 2 on each side in at least one body region (i.e. psoriasis affecting at least 10% of left and right arm, and/or 10% of left and right side of the trunk, and/or 10% of left and right leg).
- •Disease severity graded mild, moderate, severe or very severe according to the Investigator's global assessment (IGA) of disease severity on each side of the body. The assessment should be the same for both sides of the body.
- •Age 18 years or above
- •Male subjects, or females of non-childbearing potential (i.e. surgically sterile or at least two years postmenopausal)
- •Attending a hospital outpatient clinic or the private practice of a dermatologist
排除标准
- •Subjects using systemic treatments with biological therapies with a possible effect on psoriasis vulgaris within 12 weeks prior to randomisation (e.g. alefacept, efalizumab, etanercept, infliximab, adalimumab)
- •Systemic treatment with all other therapies, besides biologics, with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 4 weeks prior to randomisation (inhaled or intranasal steroids for asthma or rhinitis may be used)
- •PUVA or Grenz ray therapy within 4 weeks prior to randomisation
- •UVB therapy within 2 weeks prior to randomisation
- •Any topical treatment (except for emollients) of the trunk/limbs (except on flexures) within 2 weeks prior to randomisation
- •Topical treatment for other relevant skin disorders on the face and flexures (e.g., facial and flexural psoriasis, eczema) with potent or very potent (WHO group III-IV) corticosteroids, vitamin D analogues or retinoids within 2 weeks prior to randomisation
- •Topical treatment for other relevant skin disorders on the scalp (e.g. scalp psoriasis) with very potent (WHO group IV) corticosteroids, vitamin D analogues or retinoids within 2 weeks prior to randomisation
- •Planned initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g., beta blockers, ACE inhibitors, anti-malaria drugs, lithium) within 2 weeks prior to randomisation
- •Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4-week period prior to randomisation
- •Subjects with current participation in any other interventional clinical trial
- •Subjects with any of the following conditions present on the treatment area: eczematous skin, atopic dermatitis, clinical infection, ulcers and wounds
- •Subjects with a history of serious allergy, allergic skin rash or sensitivity to any component of the investigational products or formulations being tested
- •Subjects with positive hepatitis B, C or HIV
- •Known or suspected severe renal insufficiency or severe hepatic disorders
- •Known or suspected disorders of calcium metabolism associated with hypercalcaemia
- •Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
- •Planned exposure to the sun during the study that may affect psoriasis vulgaris (i.e., normal lifestyle outdoor activities are permitted but deliberate exposure to sunlight or artificial ultraviolet light should be avoided)
研究组 & 干预措施
3
Placebo Comparator
干预措施: Cream vehicle (Drug)
1
Experimental
干预措施: LEO 19123 Cream (calcipotriol plus LEO 80122) (Drug)
2
Active Comparator
干预措施: Dovonex® cream (Drug)
结局指标
主要结局
The Percentage Change in PASI (Psoriasis Area Severity Index)
时间窗: From baseline (Day 0) to end of treatment (Day 28)
The following formula was used to calculate the PASI for each side of the body: Upper extremities: 0.2 (R + T+ S) E = X Trunk: 0.3 (R + T+ S) E = Y Lower extremities 0.4 (R + T+ S) E = Z where: R = score for redness T = score for thickness S = score for scaliness E = score for extent The sum of X + Y + Z gives the total PASI, which can range from 0 to 64.8. The PASI used in this study is modified to exclude assessment of the head, as study treatment was not used here.
次要结局
- Participants With at Least 75% Reduction in PASI (PASI 75)(From baseline (Day 0) to end of treatment (Day 28))
- Participant's Assessment of Treatment Preference(At end of treatment (Day 28))
- The Absolute Change in PASI (Psoriasis Area Severity Index)(From baseline to end of treatment (Day 28))
- Investigator's Global Assessment of Disease Severity(At end of treatment (Day 28))
- Participants With "Controlled Disease" According to the Investigator's Global Assessment of Disease Severity(At end of treatment (Day 28))
- Participant's Overall Assessment of Treatment Response(At end of treatment (Day 28))
- Participants With at Least 50% Reduction in PASI (PASI 50)(From baseline (Day 0) to end of treatment (day 28))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination ProductsPsoriasis VulgarisNCT00875277LEO Pharma24
已完成
2 期
LEO19123 Cream in the Treatment of Atopic DermatitisAtopic DermatitisNCT00392067LEO Pharma75
已完成
2 期
LEO19123 Cream in the Treatment of Hand EczemaHand EczemaNCT00404196LEO Pharma75
已完成
1 期
Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)Atopic DermatitisNCT02219633LEO Pharma30
已完成
3 期
LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With PsoriasisPsoriasis VulgarisNCT02668692LEO Pharma213